Latest News

Joby Aviation shares fell after it unveiled a $500 million Resonant Sciences acquisition and $750 million equity facility, a defense pivot analysts say bolsters cash flow amid air-taxi certification costs.

CEO highlights AI-driven structural shifts in e-commerce as company narrows 2026 guidance.

Bookings surged 59% as commercial adoption accelerated and production applications grew.

What Happened? A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was comple...

What Happened? A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was comple...

What Happened? A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was comple...

After raising $5 billion in new capital in late April, Ackman and his team wasted no time putting money to work.

The lunar exploration stock still looks undervalued.

IBTROZI revenue hit $23.2 million with 85% of new patient starts in first-line setting.

Two FDA applications advance as cash runway extends into 2028.

The company has a lot of milestones to reach before I might be interested in investing in it.

As AI fuels demand for power, these companies are well-positioned to meet the moment.

Stafman liquidated 79% of his equity position through indirect entities after the stock surged 159% over the past year. He retains ~133,000 shares worth approximately $32.9 million.

Rocket Lab's future is riding on Neutron's success.

Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo.

Data and AI segment returns to sequential growth as company pivots toward AI-first strategy.

Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M.

SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.

Lumentum's fiscal Q4 2026 revenue grew over 110%, margins expanded, and guidance calls for 130% YOY growth, prompting analysts to affirm bullish price targets on LITE stock.

Licensing revenue from AI models is driving higher sales and margins.

Record backlog of $557.2 million fuels 44% adjusted EBITDA growth guidance for fiscal 2027.

Life science and residential assets now drive over 75% of the portfolio.

CEO Goyal warns geopolitical tensions and inflation pressured volume and margins.

Equipment momentum and tariff refunds drive $820M in quarterly sales and 45.8% EBITDA growth.

Record quarterly sales and EBITDA growth driven by aerospace demand and acquisitions.